Frankfurt
19.06.26 | 08:03
0,067 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.06. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2025 | 1 | Cision News | ||
| 05.06. | Klaria Pharma Holding AB: Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK | 125 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes... ► Artikel lesen | |
| 29.05. | Klaria Pharma Holding AB: Klaria Interim Report Q1 2026 | 159 | GlobeNewswire (Europe) | Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim reportFirst quarter of 2026 The group in total - Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.05. | KLARIA PHARMA HOLDING AB: Klaria adjusts annual report release date | 1 | Cision News | ||
| 25.05. | Klaria Pharma Holding AB: Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ) | 283 | GlobeNewswire (Europe) | With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959-2917, are hereby invited to attend the Annual General... ► Artikel lesen | |
| 22.05. | KLARIA PHARMA HOLDING AB: Klaria postpones interim Q1 report | 1 | Cision News | ||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria postpones publication of the annual report | 2 | Cision News | ||
| 23.04. | Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 05.04. | KLARIA PHARMA HOLDING AB: Annula Genernal Meeting Date Change: Klaria Pharma Holding (publ) | 2 | Cision News | ||
| 19.03. | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 19.03. | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 326 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 02.03. | Klaria Pharma Holding AB (publ) Summons to Extraordinary General Meeting | 2 | Cision News | ||
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 693 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 23.12.25 | Klaria Pharma Holding AB: Klaria accelerates its business development work in collaboration with BDO | 825 | GlobeNewswire (Europe) | With Klaria's product, Sumatriptan Alginate Film, approved in the EU and set to launch in 2026 in the largest EU markets, the company has now engaged BDO LLP's UK Life Sciences & Healthcare M&A team... ► Artikel lesen | |
| 17.12.25 | Klaria Pharma Holding AB: Klaria Receives Positive Opinion on Sumatriptan Oral Film Patent Application | 218 | GlobeNewswire (Europe) | Klaria announced earlier in the year that it had submitted an additional patent application on the sumatriptan oral film product to further protect the product and potentially extend its market exclusivity.... ► Artikel lesen | |
| 26.11.25 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2025 | 243 | GlobeNewswire (Europe) | Klaria Interim Report
1 July - 30 September 2025
Summary of the interim reportThird quarter of 2025
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.08.25 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2025 | 359 | GlobeNewswire (Europe) | Klaria interim report
1 April-30 June 2025
Summary of the interim reportSecond quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 47,500 | +0,45 % | Milliarden-Übernahmen, Kapitalmangel und Stammzelltherapien: Warum Mesoblast in einem spannenden Marktumfeld agiert | ||
| DERMAPHARM | 46,400 | -2,32 % | Lieferfähigkeit sichern: Dermapharm übernimmt Wobenzym | ||
| INCYTE | 85,94 | +0,21 % | Incyte Biosciences Japan G.K.: Incyte Japan gibt Zulassung von Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom (DLBCL) bekannt | Incyte Biosciences Japan G.K. gab heute bekannt, dass das japanische Ministerium für Gesundheit, Arbeit und Soziales (MHLW) Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,570 | -1,50 % | Green Thumb Industries Inc. - 8-K, Current Report | ||
| CHRISTINA LAKE CANNABIS | 0,020 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake investor Milia acquires 5.03M shares | ||
| PSYCHED WELLNESS | 0,007 | 0,00 % | Psyched Wellness Ltd.: Psyched Wellness Provides Corporate Update | Toronto, Ontario--(Newsfile Corp. - June 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,660 | +8,19 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| OPKO HEALTH | 1,250 | +0,81 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| COSMO | 72,00 | -2,31 % | Cosmo Pharmaceuticals N.V.: Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany | Dublin, Ireland and Heppenheim, Germany--(Newsfile Corp. - June 15, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) ("Cosmo") is pleased to announce the launch of its innovative acne cream Winlevi... ► Artikel lesen | |
| GREENRISE GLOBAL BRANDS | 0,005 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,033 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing | Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD... ► Artikel lesen | |
| MEDIPHARM LABS | 0,040 | -11,11 % | MediPharm Labs Corp.: MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders | TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,019 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Expands U.S. NCAA Athlete Platform with Multi-Sport NIL Agreement with Every True Tiger | Promino expands its U.S. NCAA NIL platform with Every True Tiger, the third-party marketing arm of the Missouri Tigers, and select student-athletes across leading sports, including football, basketball... ► Artikel lesen | |
| ADDEX THERAPEUTICS | 0,048 | 0,00 % | Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 | Geneva, Switzerland, June 22, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen |
Das Unternehmen KLARIA PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,067 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.